| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/26/2002 | WO2002074767A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074765A1 Phenyl derivatives 3 |
| 09/26/2002 | WO2002074758A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| 09/26/2002 | WO2002074752A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074751A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074750A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074749A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074748A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074743A1 Aryl-substituted alicyclic compound and medical composition comprising the same |
| 09/26/2002 | WO2002074742A2 Cdk-inhibitory indirubin derivatives having an increased solubility |
| 09/26/2002 | WO2002074735A2 Biurethane derivatives |
| 09/26/2002 | WO2002074730A1 INHIBITORS OF INTEGRIN αvβ¿6? |
| 09/26/2002 | WO2002074728A1 Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine |
| 09/26/2002 | WO2002074726A2 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | WO2002074725A1 Novel ligands of nuclear receptor superfamily, process for producing the same and use thereof |
| 09/26/2002 | WO2002074346A2 Targeting chemical compounds to cells |
| 09/26/2002 | WO2002074342A1 Remedies for arteriosclerosis |
| 09/26/2002 | WO2002074340A1 Process for producing sustained release preparation |
| 09/26/2002 | WO2002074337A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 09/26/2002 | WO2002074326A2 Urocortin-iii and uses thereof |
| 09/26/2002 | WO2002074323A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| 09/26/2002 | WO2002074320A1 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity |
| 09/26/2002 | WO2002074319A1 Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases |
| 09/26/2002 | WO2002074313A1 Drugs containing reduced vitamin b¿2? |
| 09/26/2002 | WO2002074312A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | WO2002074307A1 Treatment of restenosis |
| 09/26/2002 | WO2002074292A2 Hormone replacement therapy |
| 09/26/2002 | WO2002074249A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | WO2002074231A2 Cosmetic and dermopharmaceutical compositions comprising standardised extracts of hierochloe odorata |
| 09/26/2002 | WO2002074056A2 Allosteric adenosine receptor modulators |
| 09/26/2002 | WO2002062780A3 Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
| 09/26/2002 | WO2002060900A3 Antagonists of mcp-1 function and methods of use thereof |
| 09/26/2002 | WO2002060382A3 Novel compounds and uses thereof |
| 09/26/2002 | WO2002055517A3 4-(hetero)aryl substituted indolinones |
| 09/26/2002 | WO2002051431A9 Therapeutic and/or preventive agents for diseases due to retinal ischemia |
| 09/26/2002 | WO2002049635A3 Use of 5-aminolevulinic acid for the prophylaxis of restenosis |
| 09/26/2002 | WO2002046214A3 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/26/2002 | WO2002044126A3 Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| 09/26/2002 | WO2002038609A3 Apolipoprotein conjugates |
| 09/26/2002 | WO2002032872A8 Nitrogenous aromatic ring compounds |
| 09/26/2002 | WO2002032461A3 Protein c or activated protein c-like molecules |
| 09/26/2002 | WO2002024666A3 4-amino-quinazolines |
| 09/26/2002 | WO2002024636A3 N-acylsulfonamide apoptosis promoters |
| 09/26/2002 | WO2002000710A3 B7-like molecules and uses thereof |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001087343A3 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 09/26/2002 | WO2001085093A9 Compounds and methods for modulating cerebral amyloid angiopathy |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001076568A3 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 09/26/2002 | WO2001072695A1 Neovascularization inhibitors |
| 09/26/2002 | WO2001052847A8 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2001019823A9 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/26/2002 | WO2001015744A9 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138874 Elongase genes and uses thereof |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137944 Methods for crystallization of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine n-carboxyanhydride |
| 09/26/2002 | US20020137941 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 09/26/2002 | US20020137937 Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives |
| 09/26/2002 | US20020137933 Heterocyclic sulfonamides |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137931 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 09/26/2002 | US20020137928 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 09/26/2002 | US20020137907 Novel compounds |
| 09/26/2002 | US20020137903 Sodium dependent glucose transporters found in the intestine and kidney (SGLT2); treating diabetes |
| 09/26/2002 | US20020137801 Administering gossypol; kits to treat patients |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137769 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
| 09/26/2002 | US20020137766 Electrophysiological activity |
| 09/26/2002 | US20020137750 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137744 Metalloprotease inhibitors |
| 09/26/2002 | US20020137742 Benzenesulfonamide compounds |
| 09/26/2002 | US20020137736 Novel compounds |
| 09/26/2002 | US20020137723 Low molecular weight polymannuronate |
| 09/26/2002 | US20020137700 Nucleic acids; genetic engineering |
| 09/26/2002 | US20020137690 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 09/26/2002 | US20020137689 Hypolipidemic agents |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137666 Use of exendins and agonists thereof for the reduction of food intake |
| 09/26/2002 | US20020137205 Lipid uptake assays |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137155 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher Basidiomycetes mushroom |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137086 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| 09/26/2002 | US20020137081 Genes differentially expressed in vascular tissue activation |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |
| 09/26/2002 | US20020136819 Conserved concentrations of cocoa polyphenols by mixing carbohydrate or protein containing ingredients with a polyphenol conserving pretreatment ingredient and then with a cocoa polyphenol |
| 09/26/2002 | US20020136784 Cyclooxygenase-2 (COX-2); administering a plant extract; nonsteroidal anti-inflammatory agents |
| 09/26/2002 | US20020136775 Aldosterone receptor blockers |
| 09/26/2002 | US20020136726 Method for selectively delivering agent to arterial smooth muscle cells in mammal comprising administering agent and substance which selectively binds arterial smooth muscle cell-specific surface molecule selected from ephrin family |
| 09/26/2002 | US20020136719 For biomedical applications, including biological delivery to humans and animals |
| 09/26/2002 | US20020136717 Process for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1 binding domain or a protein having an EVH1 binding domain, and a process for detecting said interaction |
| 09/26/2002 | US20020136688 Methods for treating AVM's using radioactive compositions |